NCT04022993 - Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

July 4, 2018

Primary Completion Date

February 25, 2019

Study Completion Date

May 15, 2019

Conditions

Diabetes Mellitus, Type 1Diabetes Mellitus

Interventions

DRUG

Lantus Solostar, 100 Units/mL Subcutaneous Solution

4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses

DRUG

Insulin RinGlar, 100 Units/mL Subcutaneous Solution

4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses

Trial Locations (14)

Endocrinology Research Centre (Moscow), Moscow

Arkhangelsk Regional Clinical Hospital, Arkhangelsk

V.A. Baranov Republic Hospital, Petrozavodsk

Polyclinic Сomplex, Saint Petersburg

City Diagnostic Center № 1, Saint Petersburg

City Hospital № 2, Saint Petersburg

City Polyclinic № 117, Saint Petersburg

EosMed, Saint Petersburg

Almazov National Medical Research Centre, Saint Petersburg

Pokrovskaya Municipal Hospital, Saint Petersburg

Rostov State Medical University, Rostov-on-Don

Clinical City Hospital № 9, Saratov

Kazan Endocrinology Dispensary, Kazan'

Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky, Krasnoyarsk